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Human  peripheral blood polymorphonuclear leu- 
kocytes  (PMN's)  selectively release,  or  secrete, 
granule-associated (lysosomal) enzymes when ex- 
posed  to  appropriate  phagocytic  and  non- 
phagocytic  stimuli  (6,  7,  19-21).  Secretion  is 
dependent  upon  the  translocation of granules to 
the cell periphery and  membrane  fusion between 
granule  membranes  'and  the  plasma  membrane 
(exocytosis). These phenomena have been demon- 
strated to be influenced in reciprocal fashion by the 
cyclic  nucleotides,  cyclic  Y,5'-guanosine  mono- 
phosphate  (cGMP)  and  cyclic  Y,5'-adenosine 
monophosphate  (cAMP),  and  by  pharmacologic 
agents which are known to promote either assem- 
bly or disassembly of cytoplasmic microtubules (6, 
11,  19-21). 
Phorbol  myristate  acetate  (PMA),  a  potent 
tumor-promoter  and  proinflammatory  agent  (8, 
12), has recently been found capable of raising the 
levels  of  cGMP  in  a  variety  ot~ cell  types  (5). 
Consequently, we have investigated the effects of 
this compound upon microtubule assembly in, and 
lysosomal enzyme  release  from,  cytochalasin  B- 
treated  human  PMN's  exposed  to  two  stimuli, 
zymosan  particles  and  the  complement  compo- 
nent, C5a.  Enzyme release from stimulated cyto- 
chalasin  B-treated cells occurs  in  the  absence of 
chemotaxis  and  phagocytosis (6,  20).  Therefore, 
any  influence  that  PMA  may  have  upon  these 
processes (3)  may be disregarded, and  its effects 
upon enzyme  release per se can  be studied more 
exclusively.  Furthermore,  cytochalasin  B-treated 
cells  exposed  to  C5a  provide  the  advantage  of 
constituting a model experimental system in which 
relationships  between  microtubule  morphology 
and enzyme release may be analyzed quantitatively 
(6). 
MATERIALS  AND  METHODS 
Preparation of Cells 
Leukocyte suspensions containing approximately 85% 
PMN's were  prepared from  heparinized  venous blood 
obtained  from healthy adult donors  by employing stan- 
dard techniques of dextran sedimentation and hypotonic 
lysis of erythrocytes  (7).  The  cells were  suspended  in 
phosphate  buffer (10 mM) in  140 mM NaCi, pH 7.4, 
containing 0.6 mM CaCl~ and  1.0 mM MgCl2. Aliquots 
(2-4 ￿  l06 PMN's) were incubated with cytochalasin B 
(5 ,g/ml) (ICI Research  Laboratories, Aiderley Park, 
Cheshire,  England) in 0.1% dimethyl sulfoxide (Mathe- 
son, Coleman & Bell, East Rutherford, N. J.) at 37~  for 
l0 min. This concentration of dimethyl sulfoxide did not 
influence cell  morphology,  enzyme  release  or enzyme 
assays. 
Stimuli for L  ysosomal Enzyme Release 
After preincubation with cytochalasin B, either zymo- 
san  (0.5 mg/ml) (ICN Nutritional Biochemicals  Div., 
International Chemical  &  Nuclear Corp.,  Cleveland, 
Ohio) plus fresh autologous serum (10% vol/vol), or CSa 
(see below), was added and the reaction  mixtures were 
allowed to incubate for an additional 15 min or 5 min, 
respectively. Zymosan was suspended in 150 mM NaCI, 
boiled, washed twice, and resuspended in phosphate-buff- 
ered saline. The final particle-to-cell ratio in the reaction 
mixtures was 30:1. C5a  was generated  in fresh autolo- 
gous serum  containing  250 mM epsiion-amino-caproic 
acid (EACA) (Sigma Chemical Co., St. Louis, Mo.) by 
adding  zymosan  (l.0 mg/ml) (6,  15). After 15  rain of 
incubation  at  37~  the  serum  was  rendered  free  of 
particles by centrifugation  (3,000  ￿  g).  Previous studies 
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releasing  activity in  zymosan-treated  serum containing 
EACA (EACA-ZTS) can be attributed to its content of 
C5a (6). 
Enzyme Assays 
Following  incubation, the  reaction mixtures  were 
centrifuged  in  the  cold  (1,000  ￿  g  for  10  rain)  and 
cell-free supernates  removed for enzyme assays.  Beta- 
glucuronidase  was  determined  after  18 h  of incubation 
with  phenolphthalein  glucuronidate  as  substrate  (2). 
Lysozyme was determined by the rate of lysis of Micro- 
coccus lysodeikticus (Worthington  Biochemical Corp., 
Freehold, N.J.) measured by decrease in absorbancy at 
450 nm (18). Crystalline egg-white lysozyme (Worthing- 
ton Biochemical Corp.) was used as a standard.  Lactate 
dehydrogenase (LDH) was  measured by the method of 
Wacker et al. (16). Total enzyme activity was measured 
in  simultaneously  run  duplicate  reaction  mixtures  to 
which  had  been  added  0.2%  Triton  X-100 (Rohm  and 
Haas Co., Philadelphia, Pa.). 
Cell Viability 
The  integrity  of  PMN's  in  suspension  and  in  cell 
pellets at the conclusion  of experiments was assayed  by 
two techniques:  (a) exclusion  of eosin Y; and (b) release 
of cytoplasmic LDH, an indicator of cell death (19). 
Compounds 
PMA was the generous gift of Drs. Walter Troll and 
Andrew  Sivak  of  the  Department  of  Environmental 
Medicine,  New  York  University  School  of Medicine. 
This compound,  in dimethyl sulfoxide,  was dissolved  in 
150  mM  NaCI  to  desired  concentrations.  The  final 
concentration of dimethyl sulfoxide never exceeded 0.1%. 
Electron Microscopy 
Cells were fixed  at room temperature by a modifica- 
tion of the simultaneous fixation method of Hirsch and 
Fedorko (9). Lead citrate-stained sections were viewed in 
a Zeiss EM 9S. To eliminate observer bias, all centrioles 
visible on at least six sections from each of two specimens 
were photographed at 17,000 x  and printed at 90,000  ￿ 
on  No.  6  paper  (6)  for ease  in  microtubule counting. 
Microtubules  were  counted  from  all  of the  centriotes 
photographed.  Criteria  for  microtubule  counting  are 
described in Table II. 
RESULTS 
Effect of PMA on 
Beta-Glucuronidase  Release 
Cytochalasin  B-treated human  PMN's exposed 
to zymosan particles in the presence of autologous 
serum  for  15  min  released  22.3  a:  1.2%  of total 
beta-glucuronidase.  The  release  of this lysosomal 
enzyme was not accompanied by any enhancement 
of the release of cytoplasmic LDH or change in the 
percentage of cells which excluded eosin Y. When 
the cells were preincubated  with PMA (20 ng/ml) 
before exposure  to  zymosan,  there  was  either no 
change  or  there  was  enhancement  of  beta- 
glucuronidase release depending upon the duration 
of  preincubation  (Table  I).  Significant  enhance- 
ment (+  36.8%) of enzyme release was observed if 
PMA  was  added  l  min  before  zymosan,  but 
maximal  enhancement  (+  62,1%)  occurred  when 
the two were added simultaneously (0 min preincu- 
bation).  The  increment  in  beta-glucuronidase  re- 
lease  was  not  accompanied  by  an  increment  in 
LDH  release  or  change  in  eosin  Y  exclusion. 
Appropriate experiments revealed no evidence that 
PMA or dimethyl sulfoxide influenced the enzyme 
assays.  Furthermore,  recovery of enzymes (super- 
nate  plus  pellet) was  complete  and  there  was  no 
evidence that  any  of the  reactants  influenced  the 
total  values  measured  in  reaction  mixtures  con- 
taining Triton X-100. 
Cytochalasin  B-treated PMN's exposed to EA- 
CA-ZTS (C5a) for 5 min ,eleased 21.7  •  0.6% of 
total  beta-glucuronidase.  Lysosomal  enzyme  re- 
lease  in  this  system  was  also  enhanced  with  the 
addition  of  PMA.  The  degree  of  enhancement 
varied  with  the  concentration  of  PMA  and  the 
duration  of preincubation  (Table  I).  As  was  the 
case  with  zymosan,  the  greatest  enhancement  of 
enzyme release was observed  following very brief 
exposure  of cells to PMA. 
PMA-Induced PMN Lysozyme Release 
In the absence  of external stimuli (either zymo- 
san  or C5a),  beta-glucuronidase  was not released 
in significant amounts from cytochalasin B-treated 
PMN's  exposed  to  PMA  (Table  I).  Lysozyme, 
however, was released from these cells (Fig.  1). In 
human PMN's lysozyme-containing granules (spe- 
cifics)  appear  to  be  distinct  from  those  granules 
(azurophils)  which  contain  acid  hydrolases  and 
which  more closely resemble iysosomes of tissues 
such  as  liver  and  kidney  (14).  These  results  are 
quite  similar  to  those  previously  reported  from 
studies of normal PMN's (4,  17). 
Ultrastructure 
Cytochalasin  B-treated  cells, exposed  to  PMA 
(20 ng/ml) for 30 s,  in the presence of  10%  fresh 
autologous serum,  showed an increase, relative to 
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Enhancement by PMA of Lysosomal Enzyme Release  from Cytochalasin B-Treated Human PMN 
Enzyme Release~t 
Additions to PMN's*  Ikta-glucnronidase  LDH 
Fresh serum (Control) 
Fresh serum + PMA (20 ng/ml)w 
Zymosan (Z) 
PMA (20 ng/ml) (5 min) + Z 
PMA (20 ng/ml) (1 rain) + Z 
PMA (20 ng/ml) (0 rain) + Z 
EACA-ZTS (C5a) 
PMA (10 ng/ml) (5 min) +C5a 
PMA (10 ng/ml) (1 min) +C5a 
PMA (20 ng/ml) (5 min) +C5a 
PMA (20 ng/ml) (1 min) +C5a 
I1~g phenolphthalein/18  h per  (,4 bsorbance units per 
2  x  10" PMN's)  2  x  10  ~ PMN's) 
10.9 •  0.5  28.2 4- 1.7 
10.4 •  31.7 4- 3.5 
56.5 4- 3.1  35.2 •  3.5 
58.7 4- 1.4  33.5 4- 2.6 
73.3 4- 2.3 (+36.8%)11  30.9 4- 4.4 
84.8 4- 2.9 (+62.1%)11  35.3 4- 5.2 
55.1 4- 1.4  30.8 4- 3.1 
63.2 4- i.6  31.1 •  2.8 
80. I •  1.9 (+56.6%)11  29.7 4- 2.2 
73.6 4- 1.8 (+41.9%)11  33.2 •  3.5 
89.6 4- 2.3 (+78.1%)11  32.8 4- 4.1 
* PMN's were preincubated with cytochalasin B (5 ug/ml) for 10 min. at 37~  before additions. 
~; Total activity released  by 0.2% Triton X-100:  Beta-glucuronidase  =  253  4- 20 ug phenolphthalein/18 h/2  x  106 
PMN's; LDH  =  883 •  71  A.U./2 ￿  106 PMN's. Mean -4- SEM, N  ~  6. 
w  Cells were incubated with fresh  autologous serum (10% vol/vol) -4- PMA for 15 rain,  or with PMA for durations 
indicated before exposure to zymosan (0.5 mg/ml) plus fresh autologous serum (10% vol/voi) for 15 rain or EACA- 
ZTS (10% voi/vol) for 5 min. 
II Percent augmentation of enzyme release provoked by zymosan and C5a alone (minus control). P vs. zymosan (or 
C5a) alone <0.001. 
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FIGURE  I  PMA-induced  lysozyme  release  from  cy- 
tochalasin B-treated human PMN's. After preineubation 
with  cytochalasin  B  (5 /zg/ml for  l0 min.),  cells were 
allowed  to  incubate  for  durations  indicated  with  or 
without the addition of PMA. (A. ￿9  ￿9  A, Control; O---O, 
10  ng/ml  PMA;  O--Q,  20  ng/ml  PMA).  Lysozyme 
release  is  expressed  as  the  percent  of  total  activity 
released  by 0.2% Triton X-100. 
control  cells  (in  10%  serum),  in  the  number  of 
microtubules visible in the centriolar region (Fig. 2 
and Table II). The number of visible microtubules 
was  not significantly different from that  observed 
in cells exposed to EACA-ZTS (C5a) alone for 30 
s  (6).  Prominent  vacuole  formation,  previously 
described  by  White  and  Estensen  (17),  was  not 
observed when PMN's were exposed to PMA (20 
ng/ml) for 30 s. 
Although  there  is  no  proof that  centriolar  mi- 
crotubules  are  representative  of cytoplasmic  mi- 
crotubules,  observations  of numerous  sections  of 
PMN's  fixed  after exposure  to  PMA  (and  other 
stimuli  for  exocytosis)  (10)  indicate  that  mi- 
crotubules  in  all  portions  of  the  cytoplasm  are 
more  frequently seen in these cells than  in resting 
cells.  However,  larger  numbers  of  microtubules 
are  seen  in  the  centriolar  region,  and  differences 
due  to  experimental  manipulation  are  most 
readily  quantitated  in  this  region.  Furthermore, 
cytoplasmic microtubules  that  are not  seen  to  be 
attached  to  an  organizing  center  are  usually 
oriented  radially  with  respect  to  the  centriolar 
region, suggesting that  they originated  there. 
DISCUSSION 
Previous studies in our laboratory have established 
a  relationship between selective lysosomal enzyme 
(beta-glucuronidase)  release  from  human  PMN's 
and  cyclic  nucleotides  (6,  19-21).  Exogenous 
BRIEF NOTES  649 FIGURE 2  (a) Centriolar region of a cytochalasin  B-treated human neutrophil incubated with buffer and 
10% (vol/vol) fresh serum.  ￿  50,000. (b)  Centriolar region of a similar cell except that PMA (20 ng/ml) 
was added 30 s before fixation. Many more microtubules are visible. ￿  50,000. 
cAMP  (plus theophylline) and  agents  which  ele- 
vate cellular levels of cAMP  (e.g., prostaglandin 
El,  isoproterenol)  reduce,  whereas  exogenous 
cGMP  and  agents which elevate levels of cGMP 
(e.g.~  carbamylcholine) enhance,  enzyme  release 
from  cytochalasin  B-treated  PMN's  exposed  to 
either zymosan particles or C5a (6, 21).  We have 
also noted a  relationship between enzyme release 
and  the  potential  state  of  assembly  of  mi- 
crotubules.  Agents  which  promote  disassembly 
(e.g.,  colchicine,  vinblastine)  reduce,  whereas 
agents which promote microtubule assembly (e.g., 
deuterium  oxide) enhance,  lysosomal enzyme re- 
lease  (6,  21).  Although  it  has  been  tempting  to 
suggest  that  a  relationship exists between  cyclic 
nucleotides,  microtubules,  and  enzyme  release, 
there is, as yet, no firm evidence to support this. In 
fact,  it  is  quite  possible that  the  pharmacologic 
agents which we have studied exerted their influ- 
ence upon enzyme release by mechanisms we have 
not recognized. 
Perhaps the simplest interpretation of the results 
cited  in  this  report  is  that  PMA  enhances  the 
selective extrusion of beta-glucuronidase from cy- 
tochalasin B-treated human PMN's exposed to the 
two  different  stimuli  by  virtue  of  its  ability to 
increase cellular levels of cGMP. The requirement 
for either a  brief period of preincubation with, or 
simultaneous  addition  of,  PMA  to  enhance  en- 
zyme release is reminiscent of our previous experi- 
ence with carbamylcholine (21), and is in keeping 
with  the  observations  of  others  regarding  the 
kinetics  of  the  cGMP  response  to  PMA.  For 
example, exposure of 3T3 fibroblasts in culture to 
PMA (100 tzg/ml) resulted in a 50-fold increase of 
cGMP levels by 45 s with a decline toward control 
levels at  60  s  (5).  It  is  possible,  of course,  that 
PMA acts directly and independently to promote 
granule movement to the cell periphery and subse- 
quent  membrane  fusion between lysosomal mem- 
branes  and  plasma  membrane.  Nor  can  these 
experiments  resolve  whether  the  increase  in  mi- 
crotubule numbers observed in PMA-treated cells 
is  the  result  of enhanced  assembly (or  stability) 
(~0  BRIEF  NOTES TABLE II 
Mean Microtubule Numbers in PMA and 
Complement-Stimulated Human PMN* 
Additions to PMN's  n  Mean •  SEM 
Fresh serum (10% vol/vol)  (13)  10.7 •  0.8 
(Control) 
Fresh serum (10% vol/vol)  (13)  27.9 + 3.3:~ 
+  PMA (20 ng/ml) 
* Counted from electron micrographs at 90,000 magnifi- 
cation.  Profiles  were  considered  to  be  microtubules  if 
they had straight, parallel sides, 240-280/~ apart, were at 
least 550 A long, and were more electron dense than the 
ground  cytoplasm.  Only  those  microtubules  were 
counted that were within a 2 t~m by 2 um square centered 
upon  a  centriole.  All cells  were  pretreated  with  cyto- 
chalasin B (5 tzg/ml) for  10 min, and with additions for 
30 s before fixation. 
:tP vs. control  <0.001 
induced by PMA per se or is a secondary response 
to elevations of cGMP. 
Enhancement  of  lysosomal  enzyme  (beta- 
glucuronidase)  release from azurophil granules by 
PMA  appears  to  be  independent  of the action  of 
this  compound  on  the  release  of specific granule 
enzymes  (lysozyme).  PMA  does  not  consistently 
provoke  the  release  of  beta-glucuronidase  from 
PMN's  in  the  absence  of other  stimuli,  whereas 
no  additional  such  stimuli  are  necessary  for pro- 
voking  release  of  lysozyme.  The  facility  with 
which  specific  granule  constituents  are  extruded 
from  PMN's  in  response  to  PMA  is  apparently 
not  shared  by  primary,  or  azurophil  granules 
(lysosomes).  The  nature  of  this  difference  is 
currently  unclear,  but  may  relate  to  differences 
between  the  membranes  surrounding  the  two 
types  of granules  (1,  13),  or  to  distinct  require- 
ments for microtubule assembly. 
SUMMARY 
PMA  enhanced  release  of the  azurophil  granule 
enzyme,  beta-glucuronidase,  as  well as lysozyme, 
from  cytochalasin  B-treated  PMN's  exposed  to 
either zymosan particles or C5a.  PMA was active 
at nanomolar concentrations,  was not toxic to the 
cells, and was most effective when present for brief 
durations (0-1 min) before exposure of the cells to 
the stimuli. Beta-glucuronidase was not released in 
significant amounts from PMN's exposed to PMA 
alone, in the absence of stimuli such as zymosan or 
C5a.  In contrast, only the specific granule enzyme, 
lysozyme,  was  released  from  unstimulated  cells. 
Electron  micrographs  of  cells  exposed  to  PMA 
revealed  an  increase  in  the  number  of  visible 
cytoplasmic microtubules  as compared  to control 
cells.  Enhancement  of  lysosomal  enzyme  (beta- 
glucuronidase)  release  by  PMA  appears  to  be 
independent  of effects on  release of specific gran- 
ule enzymes (lysozyme), but rather is likely due to 
PMA-induced elevations of cellular cGMP. 
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